John B. Hawken

Director Ejecutivo en Immutep SAS .

76 años

Consumer Services

Health Technology

Perfil

John B.
Hawken is currently the Co-Chief Executive Officer at Immutep SAS since 2010.
Previously, he worked as a Principal at Aptanomics SA. He completed his undergraduate degree at the University of Oxford and holds an MBA from INSEAD.

Cargos activos de John B. Hawken

Empresas	Cargo	Inicio
Immutep SAS Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.	Director Ejecutivo	02/12/2003

Todos los cargos activos de John B. Hawken

Antiguos cargos conocidos de John B. Hawken.

Empresas	Cargo	Fin
Aptanomics SA Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France	Corporate Officer/Principal	-

Ver el detalle de la experiencia de John B. Hawken.

Formación de John B. Hawken.

University of Oxford	Undergraduate Degree
INSEAD	Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de John B. Hawken.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Immutep SAS Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.	Health Technology
Aptanomics SA Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France	Health Technology